LivaNova PLC

Equities

LIVN

GB00BYMT0J19

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
61.43 ^USD	+0.47%		-2.68%	+18.73%

May. 01	LivaNova's Q1 Adjusted Earnings, Revenue Rise, Tops Street View; Raises 2024 Guidance	MT
May. 01	Transcript : LivaNova PLC, Q1 2024 Earnings Call, May 01, 2024

LivaNova PLC Provides Financial Guidance for the Year 2022

November 02, 2022 at 06:09 am EDT

LivaNova PLC provided financial guidance for the year 2022. The company continues to expect revenue for full-year 2022 to grow between 4% and 6% on a constant-currency basis, excluding the impact of the Heart Valves divestiture.

Latest news about LivaNova PLC

LivaNova's Q1 Adjusted Earnings, Revenue Rise, Tops Street View; Raises 2024 Guidance	May. 01	MT
Transcript : LivaNova PLC, Q1 2024 Earnings Call, May 01, 2024	May. 01
Earnings Flash (LIVN) LIVANOVA Reports Q1 Revenue $294.9M, vs. Street Est of $278.2M	May. 01	MT
Earnings Flash (LIVN) LIVANOVA Posts Q1 EPS $0.73, vs. Street Est of $0.49	May. 01	MT
LivaNova PLC Provides Earnings Guidance for the Full-Year 2024	May. 01	CI
LivaNova PLC Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer	Apr. 30	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 20	MT
Sector Update: Health Care Stocks Down Wednesday Afternoon	Mar. 20	MT
LivaNova Says Sleep Apnea Study Likely to Meet Primary Efficacy Endpoint; Shares Jump	Mar. 20	MT
LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea	Mar. 20	CI
Transcript : LivaNova PLC Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:45 AM	Mar. 12
LivaNova Proposes $300 Million Private Placement of Notes	Mar. 04	MT
Barclays Adjusts Price Target on LivaNova to $61 From $57, Keeps Equalweight Rating	Feb. 27	MT
Barclays Raises Price Target on LivaNova to $61 From $57, Maintains Equalweight Rating	Feb. 26	MT
Wolfe Research Adjusts LivaNova's Price Target to $65 From $58, Keeps Outperform Rating	Feb. 22	MT
Baird Adjusts LivaNova's Price Target to $62 From $56, Keeps Neutral Rating	Feb. 22	MT
Mizuho Securities Adjusts Price Target on LivaNova to $75 From $70, Maintains Buy Rating	Feb. 22	MT
Needham Adjusts Price Target on LivaNova to $72 From $62, Keeps Buy Rating	Feb. 21	MT
Transcript : LivaNova PLC, Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
LivaNova's Q4 Adjusted Earnings, Revenue Increase; Sets 2024 Guidance	Feb. 21	MT
Earnings Flash (LIVN) LIVANOVA Reports Q4 Revenue $310.1M, vs. Street Est of $287.7M	Feb. 21	MT
Earnings Flash (LIVN) LIVANOVA Reports Q4 EPS $0.87, vs. Street Est of $0.77	Feb. 21	MT
LivaNova PLC Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Livanova plc Provides Earnings Guidance for the Full-Year 2024	Feb. 21	CI

Chart LivaNova PLC

Duration

Period

More charts

Company Profile

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Companyâs next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-06-11 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for LivaNova PLC

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

61.14 USD

Average target price

69.2 USD

Spread / Average Target

+13.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
LIVANOVA PLC	+18.73%	3.31B
ABBOTT LABORATORIES	-5.51%	182B
MEDTRONIC PLC	+2.33%	111B
BECTON, DICKINSON AND COMPANY	-3.62%	68.48B
DEXCOM, INC.	+1.52%	49.69B
CENCORA, INC.	+8.06%	44.46B
HOYA CORPORATION	+2.33%	40.67B
METTLER-TOLEDO INTERNATIONAL, INC.	+23.35%	31.22B
WEST PHARMACEUTICAL SERVICES, INC.	+0.67%	26.09B
TERUMO CORPORATION	+15.30%	25.32B

Other Medical Equipment, Supplies & Distribution